

Date: 7th March 2018

Re: Freedom of Information Request
Ref: 26- 2018

Thank you for your email dated 8th February 2018 requesting information regarding treatment.

The information that you require is as follows:

1 – How many Ovarian Carcinoma patients (any stage) have been diagnosed in the last 12 months?

110 ovarian patients were diagnosed during 2017

2 – How many stage III or IV Ovarian Carcinoma patients have received Chemotherapy for the first time in the last 12 months?

60 patients FIGO stage III-IV received first line SACT during 2017 (NB: We only record stage at presentation to CCC therefore if a patient progresses after the initial registration we would not update the stage)

Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)?

Of these, 58 were platinum based therapy

3 – How many stage III or IV Ovarian Carcinoma patients have been diagnosed as Platinum refractory (i.e. progression of disease whilst receiving Platinum therapy) or resistant (i.e. progression of disease within 6 months of last Platinum dose) in the last 12 months?

We do not record outcomes; therefore, we are unable to provide this information.

4 – How many patients with Stage III or IV Ovarian Carcinoma have been treated with the following treatments in the last 12 months? Of those how many are Platinum refractory or Platinum resistant?

Treatments Stage III or IV patients (total number) Number of Stage III or IV Platinum refractory OR Platinum resistant patients

Total Patients

PEG Liposomal Doxorubicin (Caelyx)

Gemcitabine

Paclitaxel

Docetaxel

Bevacizumab

Topotecan

Clinical trial therapy

Other – please specify

We do not electronically record platinum refractory or platinum resistant. We are therefore unable to provide this information.

5 – Within your Trust how many patients with Advanced Prostate Cancer have been treated in the past 12 months with the following treatments?

Please be aware that we have classed advanced disease as TNM stage III-IV. NB: We only record stage at presentation to CCC therefore if a patient progresses after the initial registration we would not update the stage

Treatment Patients

Abiraterone (Zytiga)

161 stage III-IV prostate patients received Abiraterone during 2017 (including Monotherapy or combination therapy)

Cabazitaxel (Jevtana)

18 stage III-IV prostate patients received Cabazitaxel during 2017

Docetaxel (Taxotere)

127 stage III-IV prostate patients received Docetaxel during 2017

Enzalutamide (Xtandi)

123 stage III-IV prostate patients received Enzalutamide during 2017 (including Monotherapy or combination therapy)

Radium-223 (Xofigo)

23 stage III-IV prostate patients received Radium 223 during 2017

6 – How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

Out of the patients receiving at least 1 cycle of either Abiraterone or Enzalutamide during 2017 (regardless of stage at presentation to CCC), 223 have been on this treatment for more than 1 year

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>